US Patent

US11541002 — Oral film compositions and dosage forms having precise active dissolution profiles

Method of Use · Assigned to Aquestive Therapeutics Inc · Expires 2040-01-31 · 14y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects oral film compositions for delivering active ingredients, including clobazam, for treating conditions such as epilepsy and seizures.

USPTO Abstract

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-724 — Onfi
U-724 — Onfi
U-724 — Onfi

Patent Metadata

Patent number
US11541002
Jurisdiction
US
Classification
Method of Use
Expires
2040-01-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Aquestive Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.